Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Post by TexRitteron Aug 15, 2018 1:49pm
193 Views
Post# 28466326

Key for Us

Key for UsNext couple of earnings. If the cannimed and medreleaf acquisitions show continued growth in med sales and Pedanios continues to show EU growth, I think the future will be extremely bright. In particular, big money companies will look at us first and foremost now that Constellation has firmly grasped Canopy. Not Aphria, but us. We have all the pieces in place; it is simply a matter of executing and the market for product proving to be as large as we believe. I actually hope that our management does not sign a deal at current price levels - barring of course a very generous price per share offer. I think - if our management team executes on all of the acquisitions over the past 12 months - our SP will climb back to the 11 - 14 dollar range with these earnings reports. That is when I am hoping for a big partner. Not now, not offering under 10 dollars per share. The only way we are below 10 dollars following next earnings report is if these balls are dropped (med sales including EU). I am still waiting to here supply news for Nova Scotia, the province that enjoys MJ use more than any other by percentage. We hired a marketing guy with roots there; getting something done to allow Aurora sales thru their provincial govt and then Aurora retail stores would be a nice little feather in the cap while we (certainly I) wait for these next few quarterlies.
Bullboard Posts